The beauty of this mutual deal between Elite and LPC was that it was fairly structured in mind to benefit and protect shareholders, and promote incentives for LPC to make a long-term commitment with Elite in achieving specific milestones such as ADT/ART opioids. As actively participating shareholders, we know Jerry and other insiders hold enormous positions of stocks and would not in anyway jeopardize its intrinsic and extrinsic values. Knowing, too, about Jerry's background as a savvy investor in the financial industry and how the market operates, he would not have agreed to the LPC deal if he thought it would not have been fair to himself, the owners, the employees, and the corporation. Simply stated, it would be like shooting himself on the foot. In Jerry We Trust. Cheers!
Forbes "...Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder, Peabody & Co..."
Market Data 
Markets 
